Targeting ALS
at Every Stage
Amyotrophic Lateral Sclerosis (ALS) is treated at all stages of the disease, with therapeutic protocols individually adapted to disease progression and functional status.
Regenerative and cellular therapy targets the core biological mechanisms driving ALS progression, including neuroinflammation, immune dysregulation and impaired cellular signaling.
Applied as a structured and adjustable medical program, therapy allows intervention at early, progressive and advanced stages of ALS, with the objective of maintaining neurological function, improving daily performance and extending functional stability over time, even as the disease evolves.
Understanding
Cellular Therapy
Cellular therapy is a medical approach that uses living cells to influence how the body responds to disease.
These cells do not replace organs or tissues. Instead, they interact with the immune and nervous systems, helping regulate inflammation, support damaged tissues and improve how the body functions at a cellular level.
Rather than acting as a one-time intervention, cellular therapy works by modifying the biological environment in which the disease progresses.
By modulating immune regulation and inflammatory activity, cellular therapy can support meaningful functional improvement, symptom stabilisation and the activation of the body’s own recovery mechanisms.
Key Therapeutic Advantages
no surgery
Stem cell therapy is delivered through precisely controlled local or intravenous administration of a biomedical cell product.
The procedure is performed using specialised medical infusion systems and fine needles, without the need for surgical instruments or operative intervention.
No General Anesthesia Required
Treatment does not require general anesthesia.
This is particularly important for elderly patients, individuals with neurological conditions, or those for whom anesthesia may pose additional medical risks.
Minimal Recovery Time
The procedure requires no special preparation and does not disrupt the patient’s daily routine.
Its non-surgical nature and absence of general anesthesia allow for a short and well-tolerated recovery period.
No risk of rejection
When clinically appropriate, therapy may involve the use of the patient’s own autologous cells, which are generally well tolerated and associated with a low risk of immune reactions.
In cases where autologous therapy is not feasible, carefully selected allogeneic cellular therapies may be applied within strict medical protocols, providing a safe and effective option for specific clinical indications.
Components of the
BioCells ALS Program
Mesenchymal
Stem Cells (MSCs)
Mesenchymal stem cells (MSCs) are multipotent regenerative cells obtained from carefully selected and certified tissue sources.
In ALS therapy, MSCs are used for their ability to modulate neuroinflammation, support the survival of remaining motor neurons and preserve neural function.
Depending on clinical indications, MSCs are obtained either from the patient’s own bone marrow (approximately 50 ml, collected under local anesthesia) or from certified donor-derived sources. All cells are isolated, expanded and prepared in a controlled laboratory environment to reach therapeutic concentration.
By strengthening neural resilience and regulating the local inflammatory environment, MSC-based therapy aims to stop progressive functional decline while enhancing functional capacity and supporting long-term neurological performance and quality of life.
Components of the
BioCells ALS Program
T-regulatory cells
(T-regs)
T-regulatory cells (T-regs) are specialised immune cells responsible for maintaining immune balance and preventing excessive or destructive inflammatory responses, particularly in sensitive neural tissues.
In ALS, T-regs play a critical role in suppressing immune-mediated damage to motor neurons and limiting secondary inflammatory processes within the brain and spinal cord that contribute to functional deterioration.
At BioCells Medical, T-reg therapy is delivered through a personalised protocol, based on either autologous cells (patient-derived) or carefully selected allogeneic cells (donor-derived), depending on clinical indications and immune status. The objective is to precisely recalibrate immune activity and restore long-term neuro-immune stability.
Through precise immune recalibration, T-reg therapy is designed to stop immune-driven functional deterioration, stabilise neurological function and relieve symptom burden, including spasticity, fatigue and speech-related impairment in selected patients.
Components of the
BioCells ALS Program
Purified concentrated
exosomes
Purified exosomes are nanoscale biological vesicles naturally released by regenerative cells, containing concentrated growth factors, regulatory proteins and micro-RNAs involved in cellular repair and intercellular communication.
In ALS therapy, exosomes function as molecular messengers, influencing key pathological processes by reducing oxidative stress, supporting neuronal signaling and improving metabolic activity within compromised neural tissue.
At BioCells Medical, exosomes are produced in our laboratory as highly purified, concentrated formulations, ensuring consistent bioactivity, controlled composition and a high safety profile prior to clinical application.
Acting at a molecular level, purified exosomes actively counteract degenerative signaling pathways and aim to stop ongoing functional loss, while enhancing neuromuscular coordination, energy efficiency and motor responsiveness — delivering measurable functional gains even in advanced stages of ALS.
Components of the
BioCells ALS Program
Personalised Neurostimulation Therapy
Neurostimulation is a non-invasive medical technology that delivers precisely controlled electrical impulses to targeted regions of the brain and spinal cord.
In ALS therapy, neurostimulation is used to reactivate weakened neural pathways, enhance functional connectivity and improve signal transmission between the central nervous system and peripheral muscles.
At BioCells Medical, neurostimulation is integrated into a personalised therapeutic protocol and applied according to the patient’s neurological profile, functional deficits and disease stage, with the goal of maximising neural responsiveness and reinforcing treatment outcomes.
By modulating neural circuits and restoring physiological signaling patterns, neurostimulation aims to stop progressive loss of neuromuscular control, while improving muscle coordination, swallowing and respiratory synchronisation, and restoring a greater sense of body stability and functional control.
Components of the
BioCells ALS Program
Peptide-Based
Protocol
Peptide therapy utilises precisely engineered biological molecules that function as cell-to-cell messengers, restoring disrupted communication within the nervous and immune systems.
In ALS, targeted peptides are applied to improve mitochondrial efficiency, support protein synthesis and regulate chronic inflammatory processes that contribute to progressive neuronal dysfunction.
At BioCells Medical, peptide therapy is incorporated into a personalised therapeutic plan through custom-tailored formulations, selected according to the patient’s metabolic profile, neurological status and disease stage, with the objective of reinforcing long-term neuroprotective and metabolic stability.
By optimising cellular signaling and energy regulation, peptide therapy aims to stop metabolic-driven functional decline, enhance muscle endurance and cognitive clarity, and maintain sustained energy balance — strengthening overall neurological performance and daily functional capacity.
Comprehensive Medical Rehabilitation
Following treatment, patients enter a structured medical rehabilitation and follow-up phase.
Each patient is supervised by a dedicated rehabilitation specialist who monitors recovery, functional status and overall well-being, providing individual recommendations and ongoing medical guidance.
Objective health data collected through a medical-grade wristband supports clinical decision-making, allowing continuous assessment of recovery dynamics and quality-of-life indicators.
SAFE FOR
EVERY stage OF LIFE
The treatment program is delivered as a non-surgical, physician-led approach under continuous medical supervision.
All therapies are individually adjusted according to the patient’s clinical condition, disease stage and age, with safety continuously prioritised throughout the treatment process.
Expected Outcomes
-
Stopping of functional decline, with improved motor control, coordination and daily mobility
-
Marked improvement in neuromuscular performance, including stronger voluntary movements, better limb coordination and increased endurance
-
Preservation and improvement of speech and swallowing function, supporting clearer communication and safer, more efficient feeding
-
Improved respiratory coordination and breathing efficiency, contributing to reduced fatigue and greater physical stability
-
Reduction and control of spasticity and muscle stiffness, allowing smoother, more controlled and purposeful movement
-
Restoration of physical energy and resilience, with improved tolerance to daily activities
-
Enhanced cognitive clarity and neurological responsiveness, supporting attention, reaction speed and mental stamina
-
Meaningful improvement in quality of life and functional independence, including in advanced stages of ALS
Clinical outcomes may vary depending on disease stage, individual biological characteristics and treatment response.
Selected Clinical and Scientific References
-
Amyotrophic Lateral Sclerosis: A Multicenter Retrospective Observational Registry
https://clinicaltrials.gov/study/NCT07143656 -
Monitoring of Outcomes of Cellular and Exosome-based Therapies in Autoinflammatory and Post-infectious Neuroinflammatory Syndromes
https://clinicaltrials.gov/study/NCT07145502 -
Proteomic Analysis of Cerebrospinal Fluid in ALS Patients Treated with Autologous Bone Marrow-Derived Mesenchymal Stem Cells
https://stemcellres.biomedcentral.com/articles/10.1186/s13287-024-03820-2 -
Optimal Therapeutic Strategy of Bone Marrow-Originated Autologous Mesenchymal Stromal/Stem Cells for ALS
https://pubmed.ncbi.nlm.nih.gov/38244235/ -
Stem Cell Therapy for Amyotrophic Lateral Sclerosis
https://pubmed.ncbi.nlm.nih.gov/26558293/ -
Stem Cells for ALS: An Overview of Possible Therapeutic Approaches
https://pubmed.ncbi.nlm.nih.gov/28088365/
Journey to Recovery
Starts Here
Personalised regenerative treatment designed around you.